大小鼠氣溶膠氣管內(nèi)給藥套裝，可輸送定量的氣溶膠到大鼠、小鼠氣管內(nèi)和肺內(nèi)，為定量化給藥提供了更好的方案：直接對(duì)大鼠、小鼠、比格犬、猴子的肺部（氣管內(nèi)）進(jìn)行定量氣溶膠霧化給藥，給藥快捷、操作方便。

有三種型號(hào)可供選擇：大鼠型氣管內(nèi)定量給藥套裝，小鼠型氣管內(nèi)定量給藥套裝，大單位氣管內(nèi)定量給藥套裝

氣管內(nèi)定量給藥裝置的主要特色：

· 定量 QUANTIFIABLE：將定量的氣溶膠給到動(dòng)物肺部

· 定時(shí) TIMED：可以在一個(gè)或多個(gè)時(shí)間點(diǎn)進(jìn)行給藥

· 有效 EFFECTIVE：氣溶膠的吸收效果好，給藥快速，效率高，操作方便

· 方便 CONVENIENCE：維護(hù)簡單，操作方便

型號(hào)：YAN

型號(hào)：YAN

大小鼠氣管內(nèi)定量給藥裝置的主要特點(diǎn)：

· 快速、精確的直接肺部給藥——?dú)馊苣z無浪費(fèi)；

· 純機(jī)械動(dòng)力，無外部空氣進(jìn)入；

· 不需加熱、推進(jìn)劑、超聲波或壓縮空氣等，對(duì)藥物物影響；

· 手持式設(shè)計(jì)，使用非常方便；

· 噴射頭頂端圓滑的設(shè)計(jì)，保證安全、溫和的插入氣管內(nèi)；

· 可高溫高壓消毒滅菌，可重復(fù)使用；

· 比其它霧化器和吸入設(shè)備提供更高濃度發(fā)藥物體積或劑量；

· 比傳統(tǒng)滴注法給藥提供更均勻的藥物分布；

另外，可選配大小鼠、大小鼠工具包套裝、大小鼠等工具，能更便捷的完成手術(shù)。

大鼠、小鼠

大小鼠工具包套裝

平臺(tái)（多種款式和型號(hào)可選）

CG-02M型，適合做小鼠，外尺寸：20*15*20cm 

CG-02R型，適合做大鼠，外尺寸：22*21*28cm

適用于大、小鼠的手術(shù)操作

CG-04M型，小鼠型

配合鐵架臺(tái)使用，多角度可調(diào)；

型號(hào)：CG-06M

多角度可調(diào)；

大小鼠通用，尺寸約：20*15*15cm

部分參考文獻(xiàn)：

1. Li, Cheng et al. “Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody.” Cell vol. 185,8 (2022): 1389-1401.e18. doi:10.1016/j.cell.2022.03.009

2. Peng, Boya et al. “Robust delivery of RIG-I agonists using extracellular vesicles for anti-cancer immunotherapy.” Journal of extracellular vesicles vol. 11,4 (2022): e12187. doi:10.1002/jev2.12187

3. Wu, Lan et al. “Poly(lactide-co-glycolide) Nanoparticles Mediate Sustained Gene Silencing and Improved Biocompatibility of siRNA Delivery Systems in Mouse Lungs after Pulmonary Administration.” ACS applied materials & interfaces vol. 13,3 (2021): 3722-3737. doi:10.1021/acsami.0c21259

4. Tian, Xidong et al. “Pulmonary Delivery of Reactive Oxygen Species/Glutathione-Responsive Paclitaxel Dimeric Nanoparticles Improved Therapeutic Indices against Metastatic Lung Cancer.” ACS applied materials & interfaces vol. 13,48 (2021): 56858-56872. doi:10.1021/acsami.1c16351

5. Gu, Peiyu et al. “Protective function of interleukin-22 in pulmonary fibrosis.” Clinical and translational medicine vol. 11,8 (2021): e509. doi:10.1002/ctm2.509

6. Su, Ruonan et al. “Venetoclax nanomedicine alleviates acute lung injury via increasing neutrophil apoptosis.” Biomaterials science vol. 9,13 (2021): 4746-4754. doi:10.1039/d1bm00481f

7. Yang, Huilin et al. “Triptolide dose-dependently improves LPS-induced alveolar hypercoagulation and fibrinolysis inhibition through NF-κB inactivation in ARDS mice.” Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 139 (2021): 111569. doi:10.1016/j.biopha.2021.111569

8. Wu, Yanqi et al. “SN50 attenuates alveolar hypercoagulation and fibrinolysis inhibition in acute respiratory distress syndrome mice through inhibiting NF-κB p65 translocation.” Respiratory research vol. 21,1 130. 27 May. 2020, doi:10.1186/s12931-020-01372-6

9. Han, Meishan et al. “Engineering of Stimulus-Responsive Pirfenidone Liposomes for Pulmonary Delivery During Treatment of Idiopathic Pulmonary Fibrosis.” Frontiers in pharmacology vol. 13 882678. 25 Apr. 2022, doi:10.3389/fphar.2022.882678

10. Wu, Lan et al. “Quantitative comparison of three widely-used pulmonary administration methods in vivo with radiolabeled inhalable nanoparticles.” European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V vol. 152 (2020): 108-115. doi:10.1016/j.ejpb.2020.05.004

11. Peng, Jianqing et al. “Carboxymethyl Chitosan Modified Oxymatrine Liposomes for the Alleviation of Emphysema in Mice via Pulmonary Administration.” Molecules (Basel, Switzerland) vol. 27,11 3610. 4 Jun. 2022, doi:10.3390/molecules27113610

    ：，

    ：

    yuyanbio

    ：yuyanbio